zur Navigation zum Inhalt
Onkologie 6. Oktober 2014

Aggressive lymphoma at ASH 2013: R-CHOP under attack?

Recent clinical data presented at the annual meeting of the American Society of Hematology challenge the predominance of R-CHOP in the first line treatment of diffuse large B cell lymphoma. New therapeutic agents such as lenalidomide and ibrutinib are tested successfully in clinical trials in combination with established therapies. Interesting results from the Austrian non-Hodgkin lymphoma (NHL)-13 trial underline the possible relevance of rituximab maintenance in specific patient subgroups. New data on unfavorable subtypes, such as double hit lymphomas, NHL at risk for central nervous system relapse, and refractory disease with CD30 expression were reported. Finally some promising therapeutic options for the unfavorable subset of extranodal NK/T-cell lymphoma were presented.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben